Last $10.66 USD
Change Today -0.40 / -3.62%
Volume 898.2K
VNDA On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 11:25 AM 03/5/15 All times are local (Market data is delayed by at least 15 minutes).

vanda pharmaceuticals inc (VNDA) Key Developments

Vanda Pharmaceuticals Inc. Announces Consolidated Financial Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Sales Guidance for the Year 2015

Vanda Pharmaceuticals Inc. announced consolidated financial results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company’s total revenues were $15.4 million, compared to $8.8 million for the fourth quarter of 2013. Net income was $69.7 million compared to a net loss of $7.7 million for the fourth quarter of 2013. Diluted net income per share was $1.77, compared to a net loss per share of $0.23 for the fourth quarter of 2013. Non-GAAP total revenues were $7.6 million, compared to $2.0 million for the fourth quarter of 2013. Non-GAAP net loss was $13.5 million compared to $12.7 million for the fourth quarter of 2013. Non-GAAP diluted net loss per share was $0.36, compared to $0.38 for the fourth quarter of 2013. Income from operations was $69.693 million against loss from operations of $7.791 million a year ago. For the year, the company’s total revenues were $50.2 million, compared to $33.9 million for 2013. Net income was $20.2 million compared to a net loss of $21.1 million for 2013. Diluted net income per share was $0.55, compared to a net loss per share of $0.69 for 2013. Non-GAAP total revenues were $19.4 million, compared to $7.1 million for 2013. Non-GAAP net loss was $80.0 million compared to $40.9 million for 2013. Non-GAAP Diluted net loss per share was $2.30, compared to $1.35 for 2013. Income from operations was $20.062 million against loss from operations of $21.200 million a year ago. The company expects ombined net product sales from both HETLIOZ and Fanapt of between $95 million and $110 million for the year 2015. HETLIOZ net product sales of between $40 million to $45 million and Fanapt net product sales of between $55 million to $65 million.

Vanda Pharmaceuticals, Inc. to Report Q4, 2014 Results on Feb 19, 2015

Vanda Pharmaceuticals, Inc. announced that they will report Q4, 2014 results at 10:00 AM, US Eastern Standard Time on Feb 19, 2015

Vanda Pharmaceuticals, Inc., Q4 2014 Earnings Call, Feb 19, 2015

Vanda Pharmaceuticals, Inc., Q4 2014 Earnings Call, Feb 19, 2015

Vanda Pharmaceuticals, Inc. - Special Call

To discuss settlement agreement with Novartis AG, commercialization plans for Fanapt, the AQW051 program and other corporate activities

Vanda Pharmaceuticals, Inc. Reaches Settlement Agreement with Novartis AG

Vanda Pharmaceuticals Inc. announced that it has reached a settlement agreement with Novartis AG related to the ongoing Fanapt license arbitration proceedings. The parties have agreed to dismiss the ongoing Fanapt arbitration and to release each other from any related claims. As a part of the settlement agreement, Novartis will transfer all US and Canadian rights in the Fanapt franchise to Vanda, make a $25 million equity investment in Vanda at a price per share equal to $13.82 and grant to Vanda an exclusive worldwide license to AQW051, a phase II alpha-7 nicotinic acetylcholine receptor partial agonist.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VNDA:US $10.66 USD -0.40

VNDA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AstraZeneca PLC 4,492 GBp +68.00
Eli Lilly & Co $70.95 USD +0.30
Pfizer Inc $34.60 USD -0.04
Sanofi €87.90 EUR +0.45
Sumitomo Dainippon Pharma Co Ltd ¥1,353 JPY +37.00
View Industry Companies
 

Industry Analysis

VNDA

Industry Average

Valuation VNDA Industry Range
Price/Earnings 19.8x
Price/Sales 8.2x
Price/Book 2.5x
Price/Cash Flow 19.2x
TEV/Sales 6.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VANDA PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.